Aug 2, 2021 4:01 pm EDT Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates
Aug 2, 2021 7:30 am EDT Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance
Jul 26, 2021 4:01 pm EDT Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients
Jun 23, 2021 7:30 am EDT Cerecor Licenses Immune Checkpoint Program from Sanford Burnham Prebys Further Expanding Pipeline of Immunology and Immuno-oncology Targets
Jun 7, 2021 7:00 am EDT Cerecor Enters Into $35 Million Debt Financing Agreement With Horizon Technology Finance
May 13, 2021 7:00 am EDT Cerecor Reports First Quarter 2021 Financial Results and Provides Business Updates
May 11, 2021 7:00 am EDT FDA Grants Fast Track Designation to CERC-002 for Treatment of Hospitalized Patients with COVID-19
May 5, 2021 7:00 am EDT Cerecor Doses First Patient in a Phase 1b Proof-of-Concept Clinical Trial of CERC-007 for the Treatment of Adult Onset Still’s Disease
Mar 29, 2021 7:00 am EDT Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002
